Computed tomography results showed that the patient maintained PR after 7 months of follow-up, and he was still in a state of progression-free survival without obvious side effects after 11 months of follow-up.<h4>Conclusion</h4>To our knowledge, this is the first case of the <i>GCC2-ALK</i> fusion type in IMT and the first report showing that the use of ensartinib as a TKI in IMT has clinical benefits. The gene discussed is ALK; the disease is inflammatory myofibroblastic tumor.